During Movember, Michaela Hagenhofer, general manager, commercial operations at Johnson & Johnson Innovative Medicine, ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

According to the 2019 National Cancer Registry the lifetime risk for prostate cancer in South Africa is 1 in every 15 man. Prostate cancer is the most common cancer in men globally and is showing a ...

Intravenous; mCRPC: Metastatic castration-resistant prostate ... Androgen deprivation is the mainstay of therapy of advanced prostate cancer treatment, but the cure rate is low and patients ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

A future in which metastatic castrate-resistant prostate ... This article provides an overview of developments in advanced prostate cancer and considers how the available options for lengthening ...

These three studies are unanimous in the conclusion that at least those men with locally advanced and metastatic prostate cancer are at increased risk of suicide during the year following diagnosis.

Combined epitope-independent microfluidic isolation and advanced staining of circulating tumour cells isolated from metastatic prostate cancer blood samples This poster presentation reports on the ...

The new use in more advanced prostate cancer patients puts the oral androgen ... with up to one-third of patients developing metastatic disease. Nubeqa is a key new therapy for Bayer as it copes ...

TOI will be one of the few community-based practices on the West Coast to offer radiopharmaceuticals in the outpatient setting.CERRITOS, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Today, the Oncology ...